Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — 9 videos in collection

More on this equity

Basilea Pharmaceutica is a Switzerland-based, commercial-stage biotech focused on treating infectious diseases. Its marketed products, Cresemba (an antifungal) and Zevtera (an anti-MRSA broad-spectrum antibiotic), are therapeutic agents against severe infection including drug-resistant strains of bacteria (eg MRSA) or fungi. The company continues to innovate to address unmet medical needs, leveraging management’s strong expertise in antifungals and antibiotics.

In this interview, CEO David Veitch provides a recap of the company’s ongoing efforts and pipeline.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free